Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CART-meso cells (BinDeBio)
- Development stage
- Unknown
- Lead developer
- BinDeBio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CART-meso cells is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Shenzhen BinDeBio Ltd. for the treatment of mesothelin-expressing solid tumors, including pancreatic and stomach cancers. The therapy utilizes a second-generation CAR construct, where a patient's own T cells are lentivirally transduced to express an anti-mesothelin single-chain variable fragment (scFv) linked to 4-1BB (CD137) costimulatory and CD3ζ signaling domains. Mesothelin is a cell surface glycoprotein that is highly overexpressed in pancreatic adenocarcinoma and other malignancies but has limited expression in normal tissues, making it a viable therapeutic target. The treatment protocol typically involves lymphodepletion with cyclophosphamide prior to infusion to improve the expansion and persistence of the CAR-T cells in the tumor microenvironment.
- Other names
- Mesothelin CAR-T cell therapyanti-mesothelin CAR-T cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on CART-meso cells (BinDeBio).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CART-meso cells (BinDeBio).